Dr. Reddy's Acquires Progynova®, Cyclo-Progynova® Trademarks in India for ₹828 Crore
Dr. Reddy's Laboratories acquired Progynova® and Cyclo-Progynova® trademarks and related assets in India from Mercury Pharma Group Limited for USD 32.15 million (approximately ₹267.76 crore). This move strengthens Dr. Reddy's gynecology portfolio and marks its entry into the Hormone Replacement Therapy segment.
The acquisition of specific trademarks and related assets for India, while strategically important for the gynecology portfolio and HRT segment entry, represents a focused expansion rather than a company-transforming mega-deal. The financial consideration is significant but within the scope of typical strategic acquisitions for a company of Dr. Reddy's size.
The acquisition of established brands like Progynova® and Cyclo-Progynova® is expected to strengthen Dr. Reddy's gynecology portfolio and facilitate entry into the Hormone Replacement Therapy segment, which is a positive development for the company's business growth.
Dr. Reddy’s Laboratories Limited has announced its acquisition of the trademarks Progynova® and Cyclo-Progynova®, along with related assets for India, from the UK-headquartered specialty pharmaceutical company Mercury Pharma Group Limited (MPGL). The transaction was finalized on February 18, 2026. This strategic move marks Dr. Reddy's entry into the Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynecology portfolio in India.
Progynova® is a leading brand in the Estradiol represented pharmaceutical market in India, with substantial physician recognition and brand recall. As of IQVIA MAT December 2025, the brand recorded sales of ₹100 crore. Cyclo-Progynova® is a combined hormone replacement therapy. M.V. Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, stated that the acquisition will spearhead their expansion into the HRT segment, leveraging their established market access to extend the reach of these brands and bring first-in-class treatments closer to patients.
The acquisition price for these trademarks and assets in India was USD 32.15 million, which is approximately ₹267.76 crore (assuming an exchange rate of ₹83.28 per USD). MPGL is not a related party to Dr. Reddy’s, thus the transaction does not fall under related party transactions. The company expects this acquisition to deliver greater impact and underscore its commitment to innovation and patient care.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.